Most Popular Stories
- Debt payments still mire HCA
- Forum: IT won't help much until practices shift operations
- Cleveland Clinic lists potential conflicts of interest online
- A new strategy for harried physicians: See patients in groups
- Fitch changes not-for-profit hospital outlook to negative
- Rapid-response teams have little effect on cardiac arrest deaths
- Disruptive doctor behavior causes mistakes, intimidates workers
- AHA survey: Negative profit margins for hospitals
- DOD, VA move to SOA architecture to build interoperable systems
- HHS: 60 percent of DME companies banned by Medicare may keep billing
- Cleveland Clinic lists potential conflicts of interest online
- A new strategy for harried physicians: See patients in groups
Poll
Featured Jobs
-
Phamacy Auditor
Pharm/DUR, Inc. - Philadelphia, PA -
Michigan Internist SLB1196tsNET
StaffPointe, LLC - northern , MI -
Tennessee Occupational Medicine
StaffPointe, LLC - near Nashville , TN -
California Physical Therapist KV1012maNET
StaffPointe, LLC - Fresno , CA -
Colorado Labor/Surg RN Manager KV1001maNET
StaffPointe, LLC - north , CO
Events
- Avaya Patient Payment Recovery Webinar
Thursday, December 11, 2008 1-2pm
Paid Research Reports
- Stakeholder Opinions: Percutaneous Coronary Intervention - Adverse events with drug-eluting stents demand a new safety standard
- Impact of Pharmacogenomics on Public Healthcare Policy
- The Cardiovascular Disorders Market Outlook to 2012
- 2008 Trends to Watch: Pharmaceutical Technology
- Pharmaceutical Pricing and Reimbursement: Strategies for market access across the US, Europe, Japan and other key geographies
Popular Topics
Studies show problems with four big-name drugs
It looks like yet another set of popular drugs are facing allegations that they pose safety risks. Drugs named this week in unfavorable studies include Fosamax, which may create heart problems for women who take it for osteoporosis and epilepsy med Dilantin, which may put young women at higher risk of developing osteoporosis. Another study concludes that diabetes drugs Avandia and Actos double or triple the odds of non-spinal fractures, particularly among patients who took the drugs for a year or more. Particularly given other drug safety controversies still very much in the public eye, this can't be giving pharma marketers a warm and fuzzy feeling.
To find out more about the studies:
- read this FiercePharma item
Related Articles:
Merck expects $1.8B hit on Fosamax
Avandia problems erode GSK profits
Takeda touts Actos as heart attack-free
Despite safety issues, Vioxx still in demand
Related Stories
- Merck agrees to $58M settlement on Vioxx ads
- Reports suggest that Merck downplayed Vioxx risks
- Statin drug probably not going OTC
- Justice Department recovers $1.12 billion from fraud
- FL sues Merck over Vioxx marketing
- CA bill would let pharmacies sell patient prescription data
- FTC: Pharmas cut 14 deals to delay generic sales in '07
- Medtronic Spine settles false claims charges for $75M
- ALSO NOTED: WellPoint exposes patient data; ED visits go up when OR trims Medicaid rolls; and much more...
- ALSO NOTED: Demand for health IT pros to soar; Pharmas lobbying hard in DC; and much more...
Comments
Post new comment
Home
| Subscribe | Advertise | Mobile Edition | RSS |
Privacy
| Site MapTHE FIERCEMARKETS NETWORKFierceFinance | FierceFinanceIT | FierceSarbox | FierceHealthcare | FierceHealthFinance | FierceHealthIT | Hospital Impact | FierceCIO | FierceCIO:TechWatch | FierceContentManagement | FierceMobileIT | FierceBiotech | FierceBioResearcher | FiercePharma | FierceVaccines | FierceIPTV | FierceOnlineVideo | FierceTelecom | FierceVoIP | FierceBroadbandWireless | FierceDeveloper | FierceMobileContent | FierceWireless | FierceWireless:Europe© 2008 FierceMarkets, Inc. All rights reserved. |
![]() |





